Health Care & Life Sciences » Pharmaceuticals | AstraZeneca PLC

AstraZeneca PLC | Balance Sheet

Fiscal year is January-December. All values GBP Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,070
4,602
4,651
4,798
3,387
4,460
Total Accounts Receivable
4,040
4,849
4,755
3,836
3,894
4,482
Inventories
1,153
1,257
1,454
1,889
2,244
2,269
Other Current Assets
857
-
-
-
-
974
Total Current Assets
12,120
10,708
10,860
10,523
9,524
12,184
Net Property, Plant & Equipment
3,513
3,854
4,351
5,542
5,629
5,827
Total Investments and Advances
390
658
671
946
1,138
847
Long-Term Note Receivable
66
132
197
487
558
258
Intangible Assets
15,715
20,863
23,371
31,760
28,101
26,434
Other Assets
1,218
581
419
452
265
204
Total Assets
33,750
37,579
40,746
50,602
46,833
47,622
ST Debt & Current Portion LT Debt
1,080
1,569
621
1,867
1,661
Accounts Payable
1,509
2,240
2,354
2,420
2,669
Income Tax Payable
1,857
1,510
1,006
1,117
998
Other Current Liabilities
5,246
5,796
6,107
6,943
6,782
Total Current Liabilities
9,691
11,114
10,088
12,347
12,111
Long-Term Debt
5,185
5,385
9,592
11,736
11,502
Provision for Risks & Charges
1,707
2,203
1,641
2,055
2,166
Deferred Taxes
979
370
930
2,310
1,335
Other Liabilities
1,421
5,125
5,060
7,773
5,799
Total Liabilities
19,711
24,979
28,188
37,112
34,531
Common Equity (Total)
14,022
12,587
12,545
12,021
11,059
Total Shareholders' Equity
14,022
12,587
12,545
12,021
11,059
Total Equity
14,040
12,600
12,558
13,490
12,302
Liabilities & Shareholders' Equity
33,750
37,579
40,746
50,602
46,833
Accumulated Minority Interest
18
12
13
1,469
1,243

About AstraZeneca

View Profile
Address
Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
United Kingdom
Employees -
Website http://astrazeneca.com
Updated 07/08/2019
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.